• Publications
  • Influence
MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients.
Orazol weekly therapy appears to be as effective as Zometa, based on the biomarkers analyzed, and a rapid decrease for all four biomarkers was seen at seven days, and was sustained throughout the study.
Abstract B57: Safety profile of zoledronic acid in a novel oral formulation
Results to date indicate Orazol is an effective and potentially safer alternative to IV ZA, which may substantially improve patients’ quality of life.